Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CencoraWBO:ABC +1.04%68 Earnings Yield (Joel Greenblatt) % is 5.56% as of Mar. 2026, which is 0% below its 10-year median of 5.58. GuruFocus rates WBO:ABC with a GF Score™ of 68/100 and a GF Value™ of €256.89 (Fairly Valued). The stock has 1 warning sign investors should review. Among 121 Medical Distribution companies, Cencora ranks worse than 57.02% on this metric.
Cencora's Enterprise Value for the quarter that ended in Mar. 2026 was €61,466 Mil.
Cencora's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €3,437 Mil. Cencora's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 5.56%.
The historical rank and industry rank for Cencora's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
WBO:ABC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26.9 Med: 5.58 Max: 10.24
Current: 5.63
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Cencora was 10.24%. The lowest was -26.90%. And the median was 5.58%.
WBO:ABC's Earnings Yield (Joel Greenblatt) % is ranked worse than 57.02% of 121
companies
in the Medical Distribution industry
Industry Median: 6.62
vs WBO:ABC: 5.63
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cencora's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Cencora Earnings Yield (Joel Greenblatt) % Related Terms
Cencora Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cencora's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cencora's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora Earnings Yield (Joel Greenblatt) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cencora's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Cencoras Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Sep. 2025 is calculated as
Cencora's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,437 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 5.56% mean?
Cencora (WBO:ABC) has a Earnings Yield (Joel Greenblatt) % of 5.56% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cencora and its competitors. This is near median its historical median of 5.58. According to the industry distribution chart, Cencora ranks #69 out of 121 companies in the Medical Distribution industry, placing it in the top 57%.
Is Cencora's Earnings Yield (Joel Greenblatt) % too high?
Cencora's current Earnings Yield (Joel Greenblatt) % of 5.56% is near median its 10-year median of 5.58. The Medical Distribution industry median Earnings Yield (Joel Greenblatt) % is 6.62. Cencora's value of 5.56% is 16% below this industry median. Based on the distribution chart, Cencora ranks #69 out of 121 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cencora has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Earnings Yield (Joel Greenblatt) % compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #69 out of 121 companies for Earnings Yield (Joel Greenblatt) %. This places Cencora in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 6.62. Cencora's value of 5.56% is 16% below this benchmark. While the company's 10-year median is 5.58 vs. the industry median of 6.62, Cencora has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Distribution company?
The median Earnings Yield (Joel Greenblatt) % among Medical Distribution companies is 6.62, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current Earnings Yield (Joel Greenblatt) % of 5.56% is 16% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cencora and its competitors. For the Medical Distribution industry, the median Earnings Yield (Joel Greenblatt) % is 6.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current Earnings Yield (Joel Greenblatt) % is 5.56%, which is near median its own 10-year median of 5.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €256.89, compared to a current price of €271.60 — trading 5.7% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 5.56%, which is near median its 10-year median of 5.58 and 16% below the Medical Distribution industry median of 6.62. Cencora's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Earnings Yield (Joel Greenblatt) % is 5.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (WBO:ABC) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of €271.60 is trading 5.7% above its estimated GF Value™ of €256.89.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for WBO:ABC:
Earnings Yield (Joel Greenblatt) %: 5.56% (near median its 10-year median of 5.58)
GF Value™: €256.89 vs. price of €271.60 (5.7% above fair value)
Industry Position: 16% below the Medical Distribution median (#69 of 121)
No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
68GF Score
Get the complete analysis for WBO:ABC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ABC has been successfully added to your 
